Exelixis
CA - Alameda
Biotechnology11 H-1B visas (FY2023)Focus: Small Molecules
Exelixis is a life sciences company focused on Small Molecules.
Oncology
Open Jobs
0
Products & Portfolio (2)
CABOMETYX
cabozantinib
Peak
ORAL · TABLET
and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
older with locally advancedmetastatic differentiated thyroid cancer (DTC)ineligible+7 more
2016
0
COMETRIQ
cabozantinib
Peak
SMORAL · CAPSULE
and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
metastatic medullary thyroid cancer (MTC)
2012
0
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 2 approved products, 100 clinical trials
Top TAs: Oncology, Gastroenterology, Hematology
H-1B (2023): 11 approvals
Portfolio Health
Peak2 (100%)
2 total products
Therapeutic Area Focus
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
11
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub